BioCentury
ARTICLE | Preclinical News

Histone modifier is implicated in epithelial-mesenchymal transition

December 11, 2017 2:02 PM UTC

In a paper published in the Journal of Cell Biology, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) identified a histone modifier that may regulate epithelial-mesenchymal transition (EMT), a process associated with tumor cell invasiveness and chemotherapy resistance.

The Genentech team, led by VP of Cancer Immunology Ira Mellman, sought to identify epigenetic regulators of EMT...

BCIQ Company Profiles

Roche